AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04902014 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Wearable Fitness Trackers
Description: Individuals assigned to this experimental condition will be given a wrist-worn WFT and will be instructed to wear it for the duration of the study. They will also download the corresponding mobile application on their smartphones. They will be trained by a member of our team on how to utilize the WFT and mobile application. The intended WFT tracks daily steps, miles traveled, kcals expended, and daily activity time. This device provides these data to the wearer via a small screen. Participants will be instructed to aim to complete at least 150 minutes of PA per week. Researchers will have the capability to track participant daily PA via the WFT and associated API. These individuals will be asked to set biweekly PA goals. These participants will also receive general physical activity guidelines education and information on strategies to reach the recommended amount of activity per week during the initial baseline assessment meeting.
Study NCT05671549 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Arthrocentesis of the temporomandibular joint
Description: Arthrocentesis of the temporomandibular joint is a minimally invasive method performed under local anesthesia to irrigate the upper temporomandibular joint cavity with biocompatible substances. The procedure aims to wash out intra-articular inflammatory substances, reduce pain and restore the function of the related joint.
Study NCT04527965 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Customized diet to reduce liver fat
Description: Ad libitum diet high in plant-derived PUFA and lower in carbohydrates~Carbohydrates: 30 E% Fat: 50 E% (PUFA 10-15 E%) Protein: 20 E%~Key foods are provided
Study NCT04527965 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Healthy Nordic diet
Description: Ad libitum diet, based on Nordic foods, high in carbohydrates (high fiber/low GI) and lower in fat~Carbohydrates: 50-55 E% Fat: 25-30 E% (PUFA 5-7.5 E%) Protein: 20 E%~Key foods are provided
Study NCT04527965 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Ad libitum diet in accordance with the Nordic Nutrition Recommendations~Key foods are provided
Study NCT03853564 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Phone-Call Intervention
Description: Mothers of the PCG arm will participate in 6-session of telephone call during which a trained collaborator will ask details on different domains of infants behavioral development.
Study NCT03001778 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usability Testing
Description: Usability testing of ready made workouts in a group format.
Study NCT04902014 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Wearable Fitness Tracker+
Description: These individuals will be given the wrist-worn WFT, be instructed to wear it for the duration of the study AND be scheduled for six SDT based MI sessions. These participants will also be trained by a member of our team on how to utilize the WFT and associated application. They will be instructed to aim to complete 150 minutes of PA per week. These participants will be asked to set biweekly PA goals which will be discussed in MI sessions. Researchers will have the capability to track participant daily PA via the WFT and associated API. These participants will also receive general physical activity guidelines education and information on strategies to reach the recommended amount of activity per week during the initial baseline assessment meeting.
Study NCT02614105 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle training
Description: 16 weeks of group-based exercise
Study NCT02614105 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cough-suppression therapy
Description: Group and individual sessions of respiratory physiotherapy with focus on techniques to suppress cough
Study NCT02614105 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control
Description: Brief information only
Study NCT01942772 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ankle-Foot Orthosis
Study NCT03946631 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: 2 hour glucose tolerance test using 75g glucose drink
Description: intervention is a 2 hour glucose tolerance test. Involves oral intake of a 75g glucose drink followed by using point of care testing. Glucose drink is taken after at least 6 hours of fasting. Fingerstick blood glucose testing done at three time points: fasting, one hour post drink and two hours post drink.
Study NCT04613947 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Informed consent
Description: The style of informing patients about the procedure they will undergo
Study NCT04613947 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Informed consent
Description: The style of informing patients about the procedure they will undergo
Study NCT04613947 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Third molar surgery
Description: Surgical extraction of the third molar tooth
Study NCT04613947 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Third molar surgery
Description: Surgical extraction of the third molar tooth
Study NCT03941366 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Standard of care chemotherapy with the change for avoidance of extensive surgery
Description: All treatments (chemotherapy, radiation, surgery) are standard of care; however, the timing of the procedures is altered to allow for the possibility of local excision instead of more extensive surgery.
Study NCT02304445 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transarterial Chemoembolization (TACE)
Description: TACE is a treatment modality where local delivery of an anti-neoplastic agent is performed through the feeding artery of the tumor followed by end embolization of the artery. The goal of TACE is to cause tumor necrosis and tumor control via acute arterial occlusion while preserving as much functional liver tissue as possible.
Study NCT02304445 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transarterial Chemoembolization (TACE)
Description: TACE is a treatment modality where local delivery of an anti-neoplastic agent is performed through the feeding artery of the tumor followed by end embolization of the artery. The goal of TACE is to cause tumor necrosis and tumor control via acute arterial occlusion while preserving as much functional liver tissue as possible.
Study NCT02304445 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: TACE+Stereotactic Body Radiotherapy
Description: This intervention adds Stereotactic Body Radiation (SBRT) to TACE therapy. SBRT is the precise administration of large doses of radiotherapy delivered over 1-5 treatments to extra-cranial tumors.
Study NCT02216994 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: high dose lactulose
Description: The patients with a score less than 5 are mostly indicative of HAD, and receive conservative therapies that included colonic irrigation, enema, high dose lactulose, and oral paraffin oil for at least 6 months. When there is no clinical improvement, patients are consented for surgical procedures to remove the dysganglionic bowel segments.
Study NCT02216994 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: conservative treatment
Description: The patients with a score less than 5 are mostly indicative of HAD, and receive conservative therapies that included colonic irrigation, enema, high dose lactulose, and oral paraffin oil for at least 6 months. When there is no clinical improvement, patients are consented for surgical procedures to remove the dysganglionic bowel segments.
Study NCT02216994 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: paraffin oil
Description: The patients with a score less than 5 are mostly indicative of HAD, and receive conservative therapies that included colonic irrigation, enema, high dose lactulose, and oral paraffin oil for at least 6 months. When there is no clinical improvement, patients are consented for surgical procedures to remove the dysganglionic bowel segments.
Study NCT03742297 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide.
Description: Lenalidomide
Study NCT03742297 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lenalidomide.
Description: Lenalidomide
Study NCT03742297 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: Carfilzomib
Study NCT03742297 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bortezomib
Description: Bortezomib
Study NCT03742297 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Daratumumab
Study NCT03742297 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone
Study NCT03742297 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Dexamethasone
Study NCT03742297 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: Prednisone
Study NCT03742297 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Melphalan
Description: Melphalan
Study NCT01722097 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rocuronium
Study NCT01722097 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT04454723 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood and/or platelet transfusion
Description: The transfused patients will receive one unit each of blood and/or platelet transfusions once a week based on CTCAE symptom grade 2 or greater of anemia and/or thrombocytopenia.
Study NCT04454723 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Complete blood count (CBC) collection
Description: CBC will be collected from patients weekly while on this protocol.
Study NCT00722865 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Avastin
Description: Given intravenously along with standard chemotherapy (Adriamycin, Bleomycin, Vinblastine and Dacarbazine) on days 1 and 15 of a 28-day cycle for a total of 6 planned cycles.
Study NCT02825550 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Taiwan ACE Beads
Description: Similar with conventional TACE, radiologist inject lipiodol with doxorubicin first, then use Taiwan ACE Beads instead of Gelfoam or polyvinyl alcohol.
Study NCT01365546 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: human VWF/FVIII concentrate
Description: intravenous infusion. Dose based on subject's individual invivo-recovery
Study NCT03461081 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: telmisartan/amlodipine and atorvastatin
Description: Telmisartan/Amlodipine(40/5 mg) 2 Tab for 10 days Telmisartan/Amlodipine(40/5 mg) 2 Tab with Atorvastatin 40 mg 1 Tab for 4 days Atorvastatin 40 mg 1 Tab for 4 days
Study NCT02566733 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remiva
Description: Target controlled infusion of remifentanil (generic drug, Remiva™)
Study NCT02566733 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ultiva
Description: Target controlled infusion of remifentanil (brand-named drug, Ultiva™)
Study NCT00760838 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin 250 mg
Description: Azithromycin 250 mg three times a week during treatment period (6 months); run-in period of 2 weeks; wash-out period of 4 weeks
Study NCT03518450 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Apex Femoral Triangle Block
Description: Nerve block that aims the vastus medialis nerve, the saphenous nerve and the anterior femoral cutaneous nerve.
Study NCT03518450 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Femoral Nerve Block
Description: Regional anesthetic technique that blocks the sensory and motor information of the femoral nerve (and it's branches).
Study NCT03518450 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Adductor Canal Block
Description: Interfascial block that targets mainly the saphenous nerve.
Study NCT03846817 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physiotherapist-led treatment
Description: 12-week of semi-standardized, progressive physiotherapist-led treatment aiming to increase hip muscle strength and load capacity.
Study NCT03366571 — intervention group
Intervention type: DRUG
Intervention: Nucleos(t)ide Analogues
Description: Entecavir 0.5mg daily, Lamivudine100mg qd daily, Adefovir Dipivoxil 10mg daily, telbivudine 600mg qd daily, their combination therapy, tenofovir 300mg qd daily.
Study NCT04243954 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PCA IV Hydromorphone (continuous dose = 0)
Description: Intravenous PCA with hydromorphone after successful titration of 24 hours. the PCA setting: 1) continuous dose = 0; 2) bolus dose = 10-20% of the total dosage of hydromorphone in the previous 24 hours: 3) lockout time = 10 minutes; 4) evaluate once every 24 hours
Study NCT04243954 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PCA IV Hydromorphone (continuous dose ≠ 0)
Description: Intravenous PCA with hydromorphone after successful titration of 24 hours. the PCA setting: 1) continuous dose (dose/hours) = the total dosage of hydromorphone in the previous 24 hours/24; 2) bolus dose = 10-20% of the total dosage of hydromorphone in the previous 24 hours; 3) lockout time = 10 minutes; 4) evaluate once every 24 hours
Study NCT04243954 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral morphine
Description: Swift to sustained-release morphine orally as background dose with immediate release morphine orally for breakthrough pain after successful titration of 24 hours.~Administration of morphine orally 1) Sustained-release morphine orally (dose/12 hours) = the total equianalgesic of the previous 24 hours/2×75% for d1; the total equianalgesic of the previous 24 hours/2 for day 2 and day 3; 2) Immediate release morphine orally = 10-20% of the total equianalgesic of the previous 24 hours; 3) Evaluate once every 24 hours
Study NCT03741621 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Viscous Fibre Blend
Description: High viscosity viscous fiber blend sprinkled on wheat and maize bran cereals(Bran Buds®; Kellogg Company)
Study NCT03741621 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Psyllium
Description: Bran Buds cereal (white bran and maize bran) with psyllium (Bran Buds® with PSY; Kellogg Company)
Study NCT03741621 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Wheat Bran
Description: All Bran cereal (All Bran®; Kellogg Company)
Study NCT02991118 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bempedoic acid
Description: bempedoic acid 180 mg tablet taken orally, once daily. Patients remain on ongoing lipid-modifying therapy (not study provided)
Study NCT02991118 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Matching placebo tablet taken orally, once daily. Patients remain on ongoing lipid-modifying therapy (not study provided)
Study NCT00760838 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo three times a week during treatment period (6 months); run-in period of 2 weeks; wash-out period of 4 weeks
Study NCT00447122 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine 1000mg/m2 30 minutes
Description: 1000mg/m2 30 minutes
Study NCT00110032 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EF5
Description: Given IV
Study NCT00110032 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional surgery
Description: Undergo surgery
Study NCT00110032 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: positron emission tomography
Description: Undergo PET
Study NCT00110032 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: fluorine F 18 EF5
Description: Given IV
Study NCT00110032 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study NCT00069706 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AL-12182 0.003% Ophthalmic Solution
Description: Investigational ophthalmic solution intended for the treatment of open-angle glaucoma or ocular hypertension
Study NCT00069706 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: AL-12182 Ophthalmic Solution Vehicle
Description: Placebo
Study NCT00069706 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Latanoprost 0.005% Ophthalmic Solution
Description: Commercially marketed ophthalmic solution intended for the treatment of open-angle glaucoma or ocular hypertension
Study NCT00069706 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AL-12182 0.01% Ophthalmic Solution
Description: Investigational ophthalmic solution intended for the treatment of open-angle glaucoma or ocular hypertension
Study NCT00069706 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AL-12182 0.03% Ophthalmic Solution
Description: Investigational ophthalmic solution intended for the treatment of open-angle glaucoma or ocular hypertension
Study NCT01264874 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D3 ( Colecalciferol)
Description: 100000 IU every 50 days for 3 years
Study NCT01264874 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: For 3 years IU every 50 days
Study NCT02845609 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sialic Acid-Extended Release
Description: Oral drug of Sialic acid
Study NCT02180932 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: periodontal pocket samples
Study NCT03021616 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: energy drink
Description: 32oz of commercially available energy drink
Study NCT03021616 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin 400mg
Description: 400mg moxifloxacin active control drink
Study NCT03021616 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo drink
Study NCT02602691 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: AlloMap®
Study NCT00447122 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lapatinib 1000mg/d
Description: 1000mg/d
Study NCT02602691 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endomyocardial biopsies
Study NCT00551421 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pertuzumab
Description: Given IV
Study NCT00551421 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cetuximab
Description: Given IV
Study NCT00551421 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan hydrochloride
Description: Given IV
Study NCT00447122 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lapatinib 1500mg/d
Description: 1500mg/d
Study NCT00551421 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunohistochemistry staining method
Description: Correlative study
Study NCT00551421 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: fluorescence in situ hybridization
Description: Correlative study
Study NCT00551421 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: gene expression analysis
Description: Correlative study
Study NCT00551421 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mutation analysis
Description: Correlative study
Study NCT00551421 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: polymerase chain reaction
Description: Correlative study
Study NCT00551421 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative study
Study NCT01838603 — intervention group
Intervention type: OTHER
Intervention: Qualitative interview
Description: Qualitative interview to sample the patients feelings, experiences and thoughts risen by the treatments in the program
Study NCT03788226 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: POF
Description: A 3-hour infusion of paclitaxel (135 mg/m2) followed by oxaliplatin (85 mg/m2) and leucovorin (400 mg/m2), administered simultaneously over a 2-hour infusion period. Subsequently, a 46-hour infusion of fluorouracil (2400 mg/m2) was administered using an ambulatory pump, repeating every 14 days for 12 cycles.
Study NCT03788226 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CAPOX/SOX/FOLFOX
Description: CAPOX: IV oxaliplatin given over 120 min at a dose of 130 mg/m2 on day 1, oral capecitabine 1000 mg/m2 twice daily on days 1 through 14 every 21 days for 8 cycles.~SOX: Oxaliplatin 130mg/m2 IV on D1 every 21 days and S-1 80mg/m2/day PO \[BSA \<1.25 40mg bid (total 80mg/day); BSA ≥1.25 - \<1.5 50mg bid (total 100mg/day); BSA ≥1.5 60mg bid (total 120mg/day)\], divided by two on D1-14 every 21 days for 8 cycles.~mFOLFOX6: IV oxaliplatin given over 120 min at a dose of 85 mg/m2 on day 1 followed by IV leucovorin 400 mg/m2 over 2h, IV bolus 5-Fluorouracil 400 mg/m2 and IV infusional 5-Fluorouracil 2400 mg/m2 over 46h every 14 days for 12 cycles.
Study NCT00836537 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Benazepril HCl 40 mg Tablets
Description: 1 x 40 mg, single-dose fed
Study NCT00836537 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lotensin® 40 mg Tablets
Description: 1 x 40 mg, single-dose fed
Study NCT01910194 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Luyxumia versus Lantus